tirzepatide mcallen tx Dr Weight-Loss Health Assessment Tirzepatide 2.5mg

Retatrutide, with its triple agonist action, could set a new benchmark in weight loss and metabolic health by aiding in weight loss and blood sugar control and also improving gut function and nutrient absorption

As of early 2026, tirzepatide does not have a dedicated J-code

Apart from the SURPASS and SURMOUNT programs, the impact of tirzepatide in people with heart failure with preserved ejection fraction and obesity and in people with nonalcoholic steatohepatitis will be assessed at the SUMMIT and A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) (SYNERGY-NASH) trial, respectively

Tirzepatide is an approved, extensively studied dual agonist with a proven safety record, commercial availability, and the most comprehensive Phase 3 dataset in the GLP-1 class